Clinical Trial Detail

NCT ID NCT03385486
Title Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Taiga Biotechnologies, Inc.
Indications

melanoma

Therapies

TBX-3400

Age Groups: adult senior

No variant requirements are available.